Serum L-lactate and pyruvate in HIV-infected patients with and without presumed NRTI-related adverse events compared to healthy volunteers

Journal of Clinical Virology

Volumn 29, Issue 1, 2004, Pages 44-50

  Ter Hofstede, Hadewych J M ^a   Willems, Hans L ^a   Koopmans, Peter P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

HIV infection; L P ratio; Lactate; Mitochondrial toxicity; Nucleoside reverse transcriptase inhibitors

Indexed keywords

BICARBONATE; LACTIC ACID; PYRUVIC ACID; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; BICARBONATE BLOOD LEVEL; BLOOD ANALYSIS; BLOOD SAMPLING; CONTROLLED STUDY; FATTY LIVER; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; INTERMETHOD COMPARISON; LACTATE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MITOCHONDRIAL TOXICITY; MYOPATHY; NEUROPATHY; OUTPATIENT CARE; PANCYTOPENIA; PRIORITY JOURNAL;

EID: 0346220189     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(03)00085-4     Document Type: Article

References (38)

1. Aggarwal A., al Talib K., Alabrash M. Type B lactic acidosis in an AIDS patient treated with zidovudine. Md. Med. J. 45:1996;929-931.
2. Bartley P.B., Westacott L., Boots R.J., Lawson M., Potter J.M., Hyland V.J., Woods M.L. Large hepatic mitochondrial DNA deletions associated with L-lactis acidosis and highly active antiretroviral therapy. AIDS. 15:(3):2001;419-420.
3. Boffito M., Marietti G., Audagnotto S., Raiter R., Di Perri G. Lactacidemia in asymptomatic HIV-infected subjects receiving nucleoside reverse-transcriptase inhibitors. CID. 34:2002;558-559.
4. Boubaker K., Flepp M., Sudre P., Furrer H., Haensel A., Hirschel B., et al. Hyperlactatemia and antiretroviral therapy: The Swiss Cohort Study. CID. 33:2001;1931-1937.
5. Brew B, Tisch S, Law M. Lactate concentrations distinguish between nucleoside neuropathy and HIV distal symmetrical sensory polyneuropathy. 8th Conference on Retroviruses and Oppurtunistic Infections 2001, Chicago; abstract 9.
6. Brinkman K. Editorial response: hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside reverse transcriptase inhibitors. CID. 31:2000;167-169.
7. Brinkman K. Management of hyperlactatemia: no need for routine lactate measurements. AIDS. 15:2001;795-797.
8. Brinkman K., ter Hofstede H.J.M. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: lactic acidosis, risk factors and therapeutic options. AIDS Rev. 1:1999;140-146.
9. Brinkman K., ter Hofstede H.J.M., Burger D.M., Smeitink J.A.M., Koopmans P.P. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS. 12:1998;1735-1744.
10. Carr A., Cooper D.A. Adverse effects of antiviral therapy. Lancet. 356:2000;1423-1430.
11. Carr A., Samaras K., Chisholm D.J., Cooper D.A. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 351:1998;1881-1883.
12. Carr A., Miller J., Law M., Cooper D.A. A syndrome of lipodystrophy (LD), lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue reverse transcriptase inhibitor therapy: contribution to PI-related LD syndrome. AIDS. 14:2000;F25-32. abstract 011.
13. Chariot P., Monnet I., Mouchet M., Rohr M., Lefaucheur J.-P., Dubreuil-Lemaine M.-L., Chousterman M., Gherardi R. Determination of the blood lactate:pyruvated ratio as a noninvasive test for the diagnosis of zidovudine myopathy. Arthritis Rheum. 37:1994;583-586.
14. Chariot P., Drogou I., de Lacroix-Szmania I., Eliezer-Vanerot M.C., Chauzaud B., Lombrès A., et al. Zidovudine induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J. Hepatol. 30:1999;156-160.
15. Côté H.C.F., Brumme Z.L., Craib K.J.P., Alexander C.S., Wynhoven B., Ting L., et al. Changes in mitochondrial DNA as marker of nucleoside toxicity in HIV-infected patients. New Engl. J. Med. 346:2002;811-820.
16. Dalakas M.C., Illa I., Pezeshkpour G.H. Mitochondrial myopathy caused by long-term zidovudine toxicity. New Engl. J. Med. 322:1990;1098-1105.
17. Delgado J., Harris M., Tesiorowski A., Montaner J.S.G. Symptomatic elevations of lactic acid and their response to treatment manipulation in human immunodeficiency virus-infected persons: a case series. CID. 33:2001;2072-2074.
18. Dube M.P. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. CID. 31:2000;1467-1475.
19. Dube M.P., Johnson D.L., Currier J.S., Leedom J.M. Protease inhibitor-associated hyperglycaemia. Lancet. 350:1997;713-714.
20. Falco V., Rodríguez D., Ribera E., Martínez E., Morí J.M., Domingo P., et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. CID. 34:2002;838-846.
21. Fouty B., Frerman F., Reves R. Riboflavin to treat nucleoside analogue-induced lactic acidosis. Lancet. 352:1998;291-292.
22. Gerard Y., Maulin L., Yazdanpanah Y. Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS. 14:2000;2723-2730.
23. ter Hofstede H.J.M., Brinkman K. Mitochondrial toxicity owing to nucleoside reverse transcriptase inhibitors: importance of clinical features and early diagnosis. Int. Antiviral News. 7:1999;148-151.
24. ter Hofstede H.J.M., de Marie S., Foudraine N.A., Danner S.A., Brinkman K. Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: four fatal cases. Int. J. STD AIDS. 11:2000;611-616.
25. Hohorst H.J. Methoden der enzymatischen analyse ed Bergmeyer. 1970;1425 Verleg Chemie, Weinheim.
26. John M., Moore C.B., James I.R. Chronic hyperlactatemia in HIV infected patients on antiretroviral therapy. AIDS. 15:2001;717-723.
27. Lai K.K., Gang D.L., Zawacki J.K., Cooley T.P. Fulminant hepatic failure associated with 2′3′-dideoxyinosine (ddI). Ann. Intern. Med. 115:1991;283-284.
28. Lewis W., Dalakas M.C. Mitochondrial toxicity of antiviral drugs. Nat. Med. 1:1995;417-422.
29. Lonergan T.J., Behling C., Pfander H., Hassanein T.I., Mathews W.C. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. CID. 31:2000;162-166.
30. Matthews P.M., Ford B., Dandurand R.J. Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease. Neurology. 43:1993;884-890.
31. Miller K.D., Cameron M., Wood L.V., Dalakas M.C., Kovacs J.A. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann. Intern. Med. 133:2001;192-196.
32. Mokrzycki M.H., Harris C., May H., Laut J., Palmisano J. Lactic acidosis associated with stavudine administration: a report of five cases. CID. 30:2000;198-200.
33. Mora S.M.C., Monzon L.M.E., Dalakas M.C. The effect of L-carnitine on the AZT-induced destruction of human myotubes. Part II: Treatment with L-carnitine improves the AZT-induced changes and prevents further destruction. Lab. Invest. 71:1994;773-781.
34. Moyle G. Mitochondrial toxicity hypothesis for lipoatrophy; a refutation. AIDS. 15:2001;413-414.
35. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New Engl. J. Med. 338:1998;853-860.
36. Stacpoole P.W. Lactic acidosis and other mitochondrial disorders. Metabolism. 46:1997;306-321.
37. Sundar K., Suarez M., Banogon P.E., Shapiro J.M. Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature. Crit. Care Med. 25:1997;1425-1430.
38. Vrouwenraets S, Treskens M, Regez RM, Troost M, Weverling GJ, Weigel HM, Frissen PHJ, Brinkman K. Hyperlactatemia in HIV-infected patients: the role of NRTI treatment (abstract 625). 8th Conference on retroviruses and opportunistic infections 2001, Chicago.